Business Wire

NTT

29.1.2020 08:34:10 CET | Business Wire | Press release

Share
Denenchofufutaba Gakuen, NTT Group Start a Joint Study to Create Smart Campus Solutions

NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT DATA Corporation, NTT COMWARE Corporation, NTT Communications Corporation, NTT Ltd., Nippon Telegraph and Telephone East Corporation (Hereinafter, NTT East)) will begin a joint study with Denenchofufutaba Gakuen in order to develop smart campus solutions that will provide safety and security at schools. NTT Group implements technology of public safety solution that will draw on the proven implementation for the City of Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005916/en/

1. Background

In recent years, there have been several crimes and incidents involving students in school facilities, and resulting in requests to improve safety measures in addition to crime prevention activities by national and local governments. Furthermore, with the introduction of new educational guidelines, the workload of teachers is increasing, and there is a growing need for efficient and effective safety measures according to those in the field of school education. In order to respond to such needs, NTT Group aims to develop smart campus solutions that contribute to the strengthening of school safety with Denenchofufutaba Gakuen. This will leverage ICT solutions based on the system integration and application development capabilities of the public safety experience gained by providing smart city solutions*1 to the City of Las Vegas, in the United States.

2. Outline of the Joint Study

This joint study aims to build a data aggregation infrastructure that enables situational awareness of danger in the school by using high-resolution video cameras, audio sensors and IoT devices, analyze and predict dangerous events for students, and verify the solutions that contribute to strengthening school safety measures.

(1) Solution Features

The first step starts with the implementation of a system to monitor and report the traffic of vehicles and establish a system to ensure the safety of students when they move between school buildings. Through the operation of this system, the future needs of safety measures and solutions are studied to create new solutions that enables situation analysis uses AI, machine learning technology and 5G related technology.

The data aggregation infrastructure is built on the architecture of NTT's innovative Cognitive Foundation ®*2 , which enables the remote creation, management, and operation of ICT resources, from devices and networks to the cloud.

(2) Points to be verified through Joint Study

Based on the operation of the above solution, the following will be developed with Denenchofufutaba Gakuen.

1) Identification of safety measures in school facilities
2) Identification of technical issues in system integration and operations
3) Creation of solutions using ICT technology
4) Feasibility study as a repeatable campus solution

(3) Period and location of implementation

- Period: Start from February 2020
- Location: Denenchofufutaba Gakuen Campus

(4) Role of each company

NTT Group

NTT

Overall supervision and coordination among group companies

NTT DATA

Joint planning, environment set-up and solution implementation
Support for deployment and technical support of smart city solutions as per the City of Las Vegas implementation

NTT COMWARE

Multi-Orchestrator delivery and technical support

NTT Communications

Provision of cloud environment and technical support, Support for Multi-Orchestrator installation

NTT Ltd

Support for deployment and technical support of smart city solutions as per the City of Las Vegas implementation

NTT East

Provision of access network, support for network related technologies

Denenchofu Futaba Gakuen

Joint study planning support (Providing issues and needs)

3. For the Future

In the future, with the learning from this joint study with Denenchofufutaba Gakuen, NTT Group will contribute to the enhancement of school safety by creating new smart campus solutions in the second quarter of 2020.

*1 (press release) About the smart city solutions available in Las Vegas, USA
https://www.ntt.co.jp/news2018/1812/181208a.html
*2 "Cognitive Foundation" is a registered trademark of Nippon Telegraph and Telephone Corporation in Japan.

About NTT

NTT is a Global Technology and Business Solutions Provider. We help clients accelerate growth and innovate new digital business models of the future. We provide business consulting and technology services for global networks, cybersecurity, managed IT and applications, workplace, datacenter and cloud services all supported by our deep industry expertise and innovation.

As a top five Global IT Services provider, our globally diverse and inclusive workforce supports clients in 80+ countries and regions. This includes 85% of the Fortune Global 100 companies and thousands of other clients and communities. With a 120-year heritage of service, innovation and social responsibility, we always advocate and act for our clients and a sustainable future. For more information on NTT, visit www.global.ntt/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye